ADMA Investors Have Opportunity to Lead ADMA Biologics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

The Schall Law Firm is seeking investors to join a class action lawsuit against ADMA Biologics, Inc. for securities fraud. The company allegedly made false and misleading statements, engaged in undisclosed related party transactions, used channel stuffing to inflate revenue, and failed to maintain proper internal controls during the period from August 9, 2024 to March 25, 2026.